EGFR and breast carcinoma: The data in this work also show that both paclitaxel and GM-4-53 co-downregulate both amphiregulin (AREG) and epiregulin (EREG) mRNAs, which are required for breast luminal development (by EGF binding/activating EGFR (ERBB)), and, when overexpressed, are linked to aggressive breast cancers of diverse type (ER + erb2, HER2 and TNBC) [72,73,74,75,76].